Andere talen TriSalus Life Sciences, Inc.

Aandelen

TLSI

US89680M1018

slotkoers Nasdaq Andere beurzen 00:00:00 04-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,36 ^USD	-1,74%		-6,84%	-12,90%

03/06	TriSalus Life Sciences, Inc. benadrukt klinische gegevens van Fase 1b Perio-02 klinische studie	CI
30/05	TRISALUS LIFE SCIENCES, INC. : Canaccord Genuity handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting	03/06
TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial	03/06
TriSalus Life Sciences Launches Warrant Exchange Offer	24/05
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants	24/05
TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	15/05
TriSalus Reports Q1 2024 Financial Results and Business Update	15/05
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024	15/05
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	07/05
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors	07/05
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	06/05
TriSalus Life Sciences Obtains $50 Million Debt Facility	01/05
Trisalus Life Sciences, Inc. and Trisalus Operating Life Sciences, Inc. Enters into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP	30/04
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	30/04
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC	30/04
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	01/04
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Reports Q4 Revenue $5.7M	01/04
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting	26/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen TriSalus Life Sciences, Inc.

Aandelen

TLSI

US89680M1018

Andere talen

Filters